Reuters logo
BRIEF-Synergy Pharma Q2 sales $2.3 million
2017年8月9日 / 晚上8点58分 / 3 个月前

BRIEF-Synergy Pharma Q2 sales $2.3 million

Aug 9 (Reuters) - Synergy Pharmaceuticals Inc:

* Synergy Pharmaceuticals reports second quarter 2017 financial results and business update

* Q2 sales $2.3 million versus I/B/E/S view $2 million

* Synergy Pharmaceuticals Inc - ‍FDA has accepted for review SNDA for Trulance for treatment of adults with IBS-C​

* Synergy Pharmaceuticals Inc - ‍PDUFA date for Trulance is January 24, 2018​

* Synergy Pharmaceuticals Inc qtrly net loss per common share $0.23

* Q2 earnings per share view $-0.25, revenue view $2.0 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below